Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24505981 | 0.98 | OXTR (0.48) | OXTRHSD11B1 | |
| SCHEMBL11122795 | 0.96 | OXTR (0.49) | OXTRHSD11B1 | |
| SCHEMBL15717910 | 0.91 | OXTR (0.51) | OXTRHSD11B1 | |
| SCHEMBL29790904 | 0.82 | OXTR (0.46) | OXTRHSD11B1 | |
| SCHEMBL762110 | 0.82 | HTR2C (0.49) | OXTRHSD11B1 | |
| SCHEMBL30085857 | 0.82 | HTR2C (0.49) | OXTRHSD11B1 | |
| SCHEMBL240993 | 0.82 | OXTR (0.46) | OXTRHSD11B1 | |
| SCHEMBL1115211 | 0.82 | OXTR (0.46) | OXTRHSD11B1 | |
| Hydrochloric Acid SCHEMBL7383656 | 0.80 | OXTR (0.55) | OXTRHSD11B1 | |
| SCHEMBL746185 | 0.80 | OXTR (0.48) | OXTRHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774060-B2 | Oxone-aceton mediated metal free preparation of syn-diols | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2020-09-15 | — | — | US | disclosed |
| US-20160168114-A1 | Oxone-Aceton Mediated Metal Free Preparation of Syn-Diols | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-06-16 | — | — | US | disclosed |
| WO-2014207766-A1 | OXONE-ACETONE MEDIATED METAL FREE PREPARATION OF SYN-DIOLS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-12-31 | — | — | WO | disclosed |
| EP-2064182-A1 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | High Point Pharmaceuticals, LLC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-2038255-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | High Point Pharmaceuticals, LLC (US) | 2009-03-25 | — | — | EP | disclosed |
| EP-2010479-A1 | 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-2007722-A1 | ADAMANTANE DERIVATIVES FOR THE TREATMENT OF THE METABOLIC SYNDROME | High Point Pharmaceuticals, LLC (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1999098-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | High Point Pharmaceuticals, LLC (US) | 2008-12-10 | — | — | EP | disclosed |
| EP-1979311-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2008006703-A1 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007144394-A2 | PHARMACEUTICAL USE OF SUBSTITUTED PIPERIDINE CARBOXAMIDES | HIGH POINT PHARMACEUTICALS, LLC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007115935-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007107550-A1 | ADAMANTANE DERIVATIVES FOR THE TREATMENT OF THE METABOLIC SYNDROME | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007101864-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007071766-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2007-06-28 | — | — | WO | disclosed |
| EP-0863118-A1 | Preparation of Brominated Indanes | ALBEMARLE CORPORATION (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5710354-A | Preparation of brominated indanes | ALBEMARLE CORPORATION (US) | 1998-01-20 | — | — | US | disclosed |
| US-4172093-A | Pharmacodynamically active indan derivatives | AB KABI (SE) | 1979-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168114-A1 | Oxone-Aceton Mediated Metal Free Preparation of Syn-Diols | SQLE, OXER1, OXA1L | OXTR 459/4885HSD11B1 108/4885 |
| US-10774060-B2 | Oxone-aceton mediated metal free preparation of syn-diols | SQLE, OXER1, OXA1L | OXTR 459/4885HSD11B1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.